Oragenics appoints Board member Kim Murphy as CEO

– USA, FL –  Oragenics, Inc. (NYSE American: OGEN), a biotech company dedicated to fighting infectious diseases including coronaviruses, today announced the appointment of Board member Kim Murphy as President and CEO, effective June 23, 2022.

Ms. Murphy who joined the Board in 202,  brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’s HPV/Gardasil Franchise.

“As a Board Member, Ms. Murphy’s extensive experience in the vaccine industry has provided valuable insight for Oragenics’ corporate and development strategies. Her proven leadership and execution will continue to elevate the potential of the Company and our pipeline programs. We are excited to have her strategic vision further implemented serving as President and CEO,” said Board Chairman, Fred Telling.

About Kimberly Murphy

Most recently Ms. Murphy served as VP of the Influenza Franchise and Global Vaccine Commercialization Leader at GSK, with responsibility for the global influenza vaccines business, and also served as VP and Global Marketing Head for GSK’s shingles vaccine, SHINGRIX. Earlier Ms. Murphy was VP and Lead for the North America Vaccines Integration Planning Team where she integrated GSK’s acquisition of Novartis AG’s vaccine division and served as VP of U.S. Vaccines Customer Strategy and as Senior Director of U.S. Influenza Portfolio Strategy. She also had distinguished vaccine leadership careers at Merck & Co., Inc. and Novartis.

Ms. Murphy currently serves as a Director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as Chairperson of Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT). She previously served in Board and advisory roles for a privately held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council, and the Saint Joseph’s University Pharmaceutical & Healthcare Marketing MBA Program.

“I am honored to be appointed as the President and CEO and excited to create additional meaningful impact to accelerate growth and lead our team,” commented Kimberly Murphy. “I look forward to cultivating our strategic business and development objectives and creating value for our stakeholders opportunistically.”

Ms. Murphy holds a BA from Old Dominion University and an MBA from Saint Joseph’s University and completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.

About Oragenics, Inc.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health and the National Research Council of Canada with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

For more information: https://www.oragenics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.